In the News
In 1973, as President Richard M. Nixon escalated an unauthorized bombing campaign in Cambodia, Sen. J. William Fulbright (D-Ark.) asked, "Does the President assert — as kings of old — that as Commander in Chief he can order American forces anywhere for any purpose that suits him?" Later that year, Congress answered unequivocally that he could not, overriding a presidential veto to authorize the War Powers Act.
Kudos to Ro Khanna for
award, peace leadership
Congratulations to Ro Khanna, our District 17 Congressman, for receiving the Friends Committee on National Legislation's annual Edward F. Snyder Award for National Legislative Leadership in Advancing Disarmament and Building Peace.
FCNL honored Representative Khanna for his work to prevent war with North Korea, his strong call to end U.S. support for the Saudi-led war in Yemen and his work to strengthen U.S. diplomacy abroad.
Government agencies would have to create better digital services for citizens under legislation passed Thursday in the House by voice vote.
The bipartisan 21st Century Integrated Digital Experience Act (IDEA) broadly aims to update the government's digital footprint by requiring that public-facing agency websites have a "consistent look" and are compliant with the web standards developed by the Technology Transformation Services of the General Services Administration. Ro Khanna, D-Calif., introduced the legislation in May.
WASHINGTON—Senators frustrated with Saudi Arabia following the killing of journalist Jamal Khashoggi could vote as early as Wednesday on a measure withdrawing U.S. support for the Saudi intervention in Yemen's civil war, a move that could put them at odds with the White House.
The Senate was expected to vote this week on a resolution to withdraw U.S. military support from the Yemen conflict, which pits a Saudi-led coalition against Iran-allied Houthi militants and has produced the world's worst humanitarian disaster.
On this week's interview episode, Nilay is joined by Rep. Ro Khanna (D-CA) and Verge policy reporter Makena Kelly to discuss Congress' plans to regulate Big Tech in the new year. Earlier this month, Democrats were able to take back a majority in the House of Representatives, and after blockbuster events this year like Facebook's Cambridge Analytica scandal, lawmakers are gearing up to rein in these Silicon Valley giants.
The Congressional Progressive Caucus, which has historically lacked the clout of other values-based congressional factions, is making a serious play for influence in the next Congress.
In the recent midterm elections, the caucus' political action committee spent more than three times what it spent in the previous election cycle.
The money paid off. The CPC is on track to pick up 19 more members: 25 people from the incoming freshman class and two incumbents ― California Reps. Jimmy Panetta and Brad Sherman. Eight of its current members are retiring.
The recent confirmation of Brett Kavanaugh to the Supreme Court and Republicans' 2016 stonewalling of Merrick Garland have upended liberals' view of the Supreme Court as a protector of key constitutional rights. Now, progressives are starting to talk about how to challenge the power of the sitting Supreme Court.
U.S. Rep. Ro Khanna (D- Calif.) introduced a legislation to award the Congressional Gold Medal to civil rights icon the Rev. James Lawson, who celebrated his 90th birthday this year.
The legislation was introduced on November 14 with more than two dozen co-sponsors.
Even as the final votes are being tallied in the midterm elections, it's clear that Democrats' majority in the House next year will be a boon for the Bay Area's congressional delegation.
Many of the area's lawmakers — all of whom are Democrats — are poised to run key committees or are angling to be elected to party leadership. Bay Area lawmakers are poised to play key roles on issues from immigration to the environment, voting rights to health care.
Here's an in-depth look at what local representatives will be up to:
The problem with prescription drugs is simple: The U.S. government bestows long-term monopolies on pharmaceutical companies, immunizing them from the forces of market competition and public regulation. As a result, Americans shoulder the highest drug prices in the world while receiving significantly poorer public health outcomes than most of the developed world.